NYSE
$1.83▲ 2.81%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $3.9MShares out 2.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.13Pre-market26.10.13 13:15filedEFFECTOther#●●●#●●●
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. received SEC effectiveness approval for its registration statement on October 9, 2026. This approval officially authorizes the company to proceed with the issuance and sale of securities as detailed in the registration statement.…more
$1.83+2.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.13Pre-market26.10.13 13:15filedEFFECTOther
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. received notice that its registration statement became effective as of October 9, 2026. This SEC filing confirms that the company's registration is officially effective, completing the necessary legal requirements for future capital raising or share issuance.…more
$1.83+2.81%vs prev closeView filingShare - 10.9After-hours26.10.10 06:15424B3Offering
Can-Fite BioPharma Ltd.
Can-Fite BioPharma has filed a prospectus for the resale of up to 6,589,796 ordinary shares (represented by 3,294,898 ADSs) issuable upon the exercise of warrants. This registration facilitates potential sales by selling shareholders, and the company will not receive proceeds from these sales unless warrants are exercised. The company is currently developing clinical-stage drug candidates for cancer and inflammatory diseases but has not yet received commercial approval for any products.…more
$1.83+2.81%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.28Regular26.09.29 03:00Bullish#●●●
Can-Fite BioPharma Files Prospectus For Offering ~6.599M Shares By Selling Shareholders…more
Can-Fite BioPharma has filed a prospectus for the potential sale of approximately 6.599 million ordinary shares by existing selling shareholders. This filing facilitates the resale of existing shares and does not involve new capital raising by the company.…more
$1.83+2.81%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.8Pre-market26.09.08 21:30
●●●●●●●● ●●●●● ●●●●●●
Can-Fite Biofarma reported a loss per share of $1.24, which beat analyst expectations of $1.43. While the loss narrowed compared to the previous year, revenue remained flat at $202,000.…more
$1.83+2.81%vs prev closeShareBenzinga - 9.8Pre-market26.09.08 21:20
●●●●●●●● ●●●●● ●●●●●●
Can-Fite announced positive clinical updates, including extended survival in its Phase III liver cancer study and progress in its pancreatic cancer pipeline. Despite these developments, the company continues to report stagnant revenue and ongoing operating losses, highlighting continued financial pressure.…more
$1.83+2.81%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report